Livro

ANF: Associação Nacional de Farmácias; AR: Assembleia da República; ARS: Administração Regional de Saúde; ARSLVT: Administração Regional de Saúde de Lisboa e Vale do Tejo; ARVs: Anti-retrovirais; BCoDE: Current and future Burden of Communicable Diseases in the European Union and EEA / EFTA countries; BSE: Encefalopatia Espongiforme de origem Bovina; CAs: Conselhos de Administração; CADs: Centros Anónimos de Deteção; CATs: Centros de Apoio aos Toxicodependentes; CDC: Centro de Controlo de Doenças dos EUA; CEE: Comunidade Económica Europeia; CEVDI: Centro de Estudo e Vigilância de Doenças Infeciosas; CNLCS: Comissão Nacional de Luta Contra a SIDA; CRS: Complexo Relacionado com a SIDA; CV; Carga Viral; DDD: Dose Definida Diária; DDOs: Doenças de Declaração Obrigatória; EU: União Europeia; DGS: Direção Geral de Saúde; ECDC: Centro de Controlo de Doenças Europeu; EUA: Estados Unidos da América; FAO: Fundo para a Alimentação e Agricultura da ONU; FCG: Fundação Calouste Gulbenkien; FSNS: Fundação para a Saúde, SNS; GPHIN: Rede Global Inteligente de Saúde Pública; HBV: Vírus da Hepatite B; HCV: Vírus da Hepatite C; HIV: Vírus da Imunodeficiência Humana; ICD10: Classificação Internacional de Doenças, 10ª Versão; IDSA: Sociedade Americana de Doenças Infeciosas; IDT: Instituto da Droga e da Toxicodependência; INFARMED: Instituto Nacional da Farmácia e do Medicamento; INSA: Instituto Nacional de Saúde; ISDS: Sociedade Internacional de Vigilância de Doenças; ISTM: Sociedade Internacional de Medicina das Viagens; MRSA: Estafilococo Meticilino-Resistente; NASA: Agência Aeronáutica Espacial Americana; OM: Ordem dos Médicos; OMS: Organização Mundial de Saúde; ONU: Organização das Nações Unidas; OPSS: Observatório Português dos Sistemas de Saúde; PALOPs: Países de Língua Oficial Portuguesa; PIB: Produto Interno Bruto; PNS: Plano Nacional de Saúde; RVS: Resposta Viral Sustentada; SARS: Sindroma Severo Respiratório Agudo; SIDA: Síndrome da Imunodeficiência Adquirida; SNS: Serviço Nacional de Saúde; UC: Universidade de Coimbra; UNAIDS: Programa da ONU para a SIDA; USD: Dólares dos EUA.

“… aqueles que não conseguirem lembrar-se do passado, estão condenados a repeti-lo…“ (George Santayana, filósofo espanhol, 1863 – 1952)

Ahmad A, Ahmad E, Rabbani G, Haque S, Arshad M, Khan RH. Identification and design of antimicrobial peptides for therapeutic applications. Curr. Protein Pept. Sci. 2012 May; 13(3): 211-23.

Alelú-Paz R, Iturrieta-Zuazo I. Human endogenous retrovirus: Their possible role in the molecular etiology of the schizophrenia. Open J. Genetics 2012; 2(2): 70-76.

Arcaini L, Merli M, Volpetti S, Rattotti S, Gotti M, Zaja F. Indolente B-cell lymphomas associated with HCV infection: Clinical and virological features and role of antiviral therapy. Clin. Dev. Immunol. 2012; 2012: 638185.

Armstrong JD, Harrison TS. Immunotherapy for fungal infections. Curr. Opin. Microbiol. 2012 Aug; 15(4): 434-9.

Arthur JC, Jobin C. The struggle within: Microbial influences on colorectal cancer. Inflamm. Bowel Dis 2011 Jan; 17(1): 396-409.

Back JVV, Langedijk JP. Structure-based design for high-hanging vaccine fruits. Adv. Immunol. 2012; 114: 33-50.

Baio P, Brucato A, Buskila D, Gershwin ME, Giacomazzi, D, Lopez LR, et al. Autoimmune diseases and infections: Clin. Exp. Rheumatol. 2008 Jan-Fev; 26 (1 suppl 48): S74-80.

Barnighausen T, Salomon JA, Sangrujee N. HIV treatment as prevention: Issues in economic evaluation. PLoS Med 2012 Jul; 9(7): e1001263.

Biek R, Real LA. The landscape genetics of infectious diseases emergence and spread. Mol. Ecol. 2010 Sep; 19(17): 3515-31

Bisht M, Bist SS. Human papilloma virus: A new risk factor of head and neck cancers. J. Cancer Res. Ther. 2011 Jul-Sep; 7(3): 251-5.

Boily MC, Masse B, Atsllaq R, Padian NS, Eaton JW, Vesga JF, Hallett TB. HIV as prevention: Considerations in design, conduct, and analysis of cluster randomized controlled trials of combination HIV prevention. PLoS Med 2012 Jul; 9(7): e 1001250.

Bonovas S, Nikolopoulos G. High-burden epidemics in Greece in the era of economic crisis: Early signs of a public health tragedy. J. Prev. Med. Hyg. 2012; 53: 169-71.

Brar T, Nagaraj S, Mohapatra S. Microbes and asthma: The missing cellular and molecular links. Curr. Opin. Pulm. Med. 2012 Jan; 18(1): 14-22.

Brock TD. Milestones in Microbiology: 1546 to 1940. 1st ed. Washington: ASM Press; 1999.

Brownlie J, Peckham C, Waage J, Woolhouse M, Lyall C, Meagher L, Tait J, Nicoll A. Foresight infectious disesases: Preparing the future threats. Office of Science and Innovation, London; 2006.

Brownstein JS, Freifeld CC, Reis BY, Mandi KD. Surveillance sans frontières: Internet-based emerging infectious disease intelligence and the health man project. PLoS Med. 2008 Jul. 8; 5(7): e151.

Brownstein JS. Digital disease detection: Harnessing the web for public health surveillance. NEJM 2009 May 21; 360(21): 2153-57

Cantor NF. In the wake of the plague: The black death and the world it made. 1st ed. London: Pocket Books and Design; 2001.

Carvalho JF, Pereira RM, Shoenfeld Y. The mosaic of autoimmunity: The role of environmental factors. Front. Biosci. 2009 Jun 1; 1; 501-9.

Cawood R, Hills T, Wong SL, Alamoudi AA, Beadle S, Fisher KD, Seymour LW. Recombinant viral vaccines for cancer. Trends Mol. Med. 2012 Sep; 18(99: 564-74.

Colombo GL, Matteo SD, Maggiolo F. Antiretroviral therapy in HIV-infected patients: A proposal to assess the economic value of the single-tablet regimen Clinico-Economics and Out. Res. 2013; 5: 59-68.

Compare D, Coccoli P, Rocco A, Nardone OM, De Maria S,Carteni M, Nardone G. Gut-liver axis: The impact of gut microbiota on the non alcoolic fatty liver disease. Nutr. Metabol. Cardiovasc. Dis. 2012 Jun; 22(6): 471-6.

Conway L. Forgotten Ellis lsand: The extraordinary story of America´s immigrant hospital. 1st ed. New York: Smithsonion´s Books; 2007

Cook ND, Lovell WG. Secret judgments of god: Old world disease in colonial Spanish America. 1st ed. Norman: University of Oklahoma Press; 1992.

Cunha BA. Historical aspects of infectious diseases, Part I. Inf. Dis. Clin. of North Am. 2004 March; 18(1): XI-XV.

Cunha BA. Historical aspects of infectious diseases, Part II. Inf. Dis. Clin. of North Am. 2004 March; 18(2): XI-XV.

Day MJ. One health: The importance of companion animal vector-borne diseases. Parasit Vectors 2011 Apr 13; 4(49).

Dimitrov NB, Meyers LA. Mathematical approaches to infectious diseases prediction and control. Informs 2010: 1-25

Dorer MS, Talarico S, Salama NR. Helicobacter pylori´s unconventional role in health and disease. PLoS Pathol. 2009 Oct; 5(10): e1000544.

Fainardi E, Castellazzi M, Seraceni S, Granieri E, Contini C. Under the microscope: Focus on chlamydia pneumoniae infection and multiple sclerosis. Curr. Neurovasc. Res. 2008 Feb; 5(1): 60-70.

Fisher A, Hacein-Bey-Abina S, Cavazzana-Calvo M. Strategies for retrovirus-based correction of severe, combined immunodeficiency (SCID). Methods Enzymol. 2012; 507: 15-27

Fisman DH. The one health paradigm: Time for infectious diseases clinicians to make a note?. Can. J. Inf. Dis. Med. Microbiol. 2010; 21(3): 111-4.

Fonkwo PN. Pricing infectious diseases: The economic and health implications of infectious diseases. EMBO Reports 2008; 9: S13-SS17.

Force, Task, et al. Infectious Disease as a Global Security Threat. by PJ. Simmons, Editor, 66.

Ford TE, Colwell RR, Rose JB, Morse SS, Rogers DJ, Yates TL. Using satellite images of environmental changes to predict infectious diseases outbreaks. Em. Inf. Dis. 2009 Sep; 15(9): 1341-46.

Frank D. President´s message: One world, one health, one medicine. CVJ 2008 Nov; 49: 1063-5.

Freedman DO, Kozarsky PE, Weld LH, Cetron MS. Geosentinal: The global emerging infections sentinel network of international society of travel medicine. Trav. Med. 1999 Jun; 6(2): 94-98.

Frieden TR, Khabbaz RF, De Cock KM. A CDC framwork for preventing infectious diseases: Sustaining the essentials and innovating for the future. CDC Oct. 2011.

Gallo RC. Reseach and discovery of the first human cancer virus, HTLV-1. Best Pract. Res. Clin, Haematol. 2011 Dec; 24(4): 559-65.

Gaynes RP. Germ theory: Medical pioneers in infectious diseases. 1st ed. Washington: ASM Press; 2011.

Giacca M, Zacchigna S. Virus-mediated gene delivary for human gene therapy. J. Contol Release 2012 Jul; 20(161): 377-88.

Gilden DH. Infectious causes of multiple sclerosis. Lancet Neirol. 2005 Mar; 4(3): 195-202.

Gonzalo T, Goñi MG, Muñoz-Fernández MA. Socio-economic impact of antirretroviral treatment in HIV patients. An economic review of cost savings after introduction of HAART. AIDS Rev 2009; 11: 79 – 90.

Hammer HF. Gut microbiota and inflamatory bowel disease. Dig. Dis. 2011; 29(6): 550-3.

Hedge NR, Kaveri SV, Bayry J. Recent advances in the administration of vaccines for infectious diseases: Microneedles, as painless delivary devices for mass vaccination. Drug Discov. Today 2011 Dec; 16(23-24): 1061-8.

Huang JX, Bishop-Hurley SL, Cooper,MA. Development of anti-infectives using phage display: Biological agents against bacteria, virus and parasites. Antimicrob. Agents Chemother. 2012 Sep; 56(9): 4569-82.

Huang YJ, Lynch SV. The emerging relationship between the airway microbiota and chronic respiratory disease: Clinical implications. Expert. Ver. Respirat. Med. 2011 Dec; 5(6): 809-21.

Humbert O, Davis L, Malzets N. Targeted gene therapies: Tools, applications, optimization. Crit. Ver. Biochem. Mol. Biol. 2012 May-Jun; 47(3): 264-281.

Ippolito G, Feldmann H, Lanini S, Vairo F, Di Caro A, Capobianchi MR, Nicastri E. Viral hemorragic fevers: Advancing the level of treatment. BMC Med. 2012 Mar 29; 10:31.

Jerusalinsky D, Baez MV, Epstein AL. Herpes simplex virus type 1/based amplicon vectors for fundamental reseach in neurociences and gene tharapy of neurological diseases. J. Physiol. Paris 2012 Jan; 106(1-2); 2-11.

Jewell CP, Kypraios T, Chirstley RM, Roberts GO. A novel approach to real-time prediction for emerging infectious diseases: A case study in avian influenza H5N1. Prev. Vet. Med. 2009; 91: 19-28

Johnston KM, Levy AR, Lima VD, Hogg RS, Tyndall MW, Gustafson P, et al. Expanding acess to HAART: a cost-effective approach for treating and preventing HIV. AIDS 2010 Jul 31; 24(12): 1929 – 35.

Kapsimali VD, Kanakis MA, Vaiopoulos GA, Kaklamanis PG. Etiopathogenesis of Behcet´s disease with enphasis on the role of immunological aberrations. Clin. Rheumatol. 2010 Nov; 29(11): 1211-6.

Kaufmann JK, Nettelbeck DM. Virus chimeras for gene therapy, vaccination, and oncolysis: adenoviruses and beyond. Trends Mol. Med. 2012 Jul; 18(7): 365-76.

Kimm JW, Gulley JL. Pxviral vectors for cancer immunotherapy. Expert Opin. Biol. Ther. 2012 Apr; 12(4):563-478.

King OD, Gitler AD, Shorter J. The tip of the iceberg: RNA-binding proteins with prion-like domains in the neurodegenerative disease. Brain Res. 2012 Jun 26; 1462: 61-80.

Klippstein R, Pozo D. Nanotechnology-based manipulation of dendritic cells for enhanced imunotherapy strategies. Nanomedicine 2010 Aug; 6(4): 523-9.

Kozarov E. Bacterial invasion of vascular cell types: Vascular infectology and atherogenesis. Future Cardiol. 2012 Jan; 8(1): 123-138.

Kretzschmar M, Mangen MJJ, Pinheiro P, Jahn B, Févre EM, Longui S, et al. New methodology for estimating the burden of infectious diseases in europe. PLos Med. 2012 Apr; 9(4): 1001205.

Krishna NK, Cunnion KM. Role of molecular diagnostics in the management of infectious diseases. Med. Clin. North A. 201;2 Nov 96(6): 1067-78.

Kroll M, Carpentes G, Wyman O. The economic and social impect of emerging infectious diseases: Mitigation through detection, research, and response. Available in www.healthcare.philips.com/…/.

Kuehn BM. Human, animal, ecosystem health all key to curbing emerging infectious disease. JAMA 2010 Jan. 13; 303(2): 117-24.

Kuhnert D, Wu CH, Drummond AJ. Phylogenetic and epidemic modeling of rapid evolving infectious diseases. Infect. Genet. Evol. 2011 Dec; 11(8): 1825-41.

Lafeuillade A. Eliminating the HIV reservoir. Curr. HIV/AIDS rep. 2012 Jun; 9(2): 121-31.

Librea JM, Ambasb JR, Domingoc P, Gatelld JM, Lozanoe F, Santosa JR, et al. Clinical implications of fixed-dos coformulations of antiretrovirals on the outcome of HIV-1 therapy AIDS Sep 10; 25(14): 1683-90.

Liu MA.DNA vaccines: An historical perspective and view to the future Immunol. Rev. 2011 Jan; 239(1): 62-84.

Liu S, Cipriano LE, Holodnly M, Owens DK, Flebert JDG. New protease inhibitors for the treatment of chronic hepatitis C> A cost/effectiveness analysis. AIM 2012; 156: 279 – 90.

Logan GJ, Alexander IE. Adeno-associated virus vectors: Immunology and potencial use for immune modulation. Curr. Gene Ther. 2012 Aug; 12(4): 333-43.

López-Fraga M, Wright N, Jiménez A. RNA interference-based therapeutics: New strategies to fight infectious diseases. Ifect. Diseas. Drug Targets. 2008 Dec; 8(4): 262-73.

Loudon I. Western medicine: An illustrated history. 1st ed. Oxford: Oxford University Press; 1997.

Lucas A, Armbruster B. The cost-effectiviness of expanded HIV screening in the United States. AIDS 2013, 27(5): 795 – 801.

Marques MG, Cule J. The great maritime discoveries and world health. 1st ed. Lisbon: ENSP / OM; 1991

McKay DM. The therapeutic helminth?. Trends Parasitol. 2009 Mar; 25(3): 109-14.

Meyer-Rath G, Over M. HIV treatment as prevention: Modelling the cost of antiretroviral treatment – State of the art and future directions. PLoS Med 2012 Jul; 9(7): e1001247.

Mills JN, Gage KL, Khan AS. Potencial influence of climate change on vector-borne and zoonotic diseases: A review and proposed research plan. Environ. Health Perspec. 2010 Nov; 118(11): 1507-14.

Morens DM, Fauci AS. Emerging infectious diseases in 2012: 20 years after the institute of medicine report. mBio 2012 Nov./Dec.; 3(6): 1-4

Nexo BA, Christensen T, Frederiksen J, Moller-Larsen A, Oturai AB, Villes P, et al. The etiology of multiple sclerosis: Genetic evidence of human endogenous retrovirus HERV-Fc1. PLOS ONE 2011; 6(2): e16652.

Nicolaldes NC, Sass PM, Grasso L. Advances in targeted therapeutic agents. Expert. Opin. Drug Discov. 2010 Nov; 5(11): 1123-40.

Nourse JP, Jones K, Gandhi MK. Epstein-Barr virus-related post-transplant lymphoproliferative disorders: Pathogenetic insights for targeted therapy. Am. J. Transplant. 2011 May; 11(5): 888-95.

Nystrom AM, Wooley KL. The importance of chemistry in creating well-defined nanoscopic embeded therapeutics: Devices capable of the dual functions of imaging and therapy. Acc. Chem. Res. 2011 Oct 18; 44(10): 969-78

Ogris M, Wagner E. To be targeted: is the magic bullet concept a viable option for synthetic nuclei acid therapeutics? Hum. Gene Ther. 2011 Jul; 22(7): 799-807.

Packard RM. The making of a tropical disease: A short history of malaria. 1st ed. Baltimore: The Johns Hopkins University Press; 2007

Pagnoux C, Cohen P, Guillevin L. Vasculitides secondary to infetions. Clin. Exp. Rheumatol. 2006 Mar-Apr; 24(2 suppl 41): S71-81.

Pert A. Endogenous retroviruses in pathogenesis of autoimmunity. The J. of Rheumatol. 2001 March 1; 28(3): 461-464.

Pitman R, Melegaro A, Gelb D, Joseph C, Cooper D, Smith G, Gerard E. The burden of ifectious diseases. Available in www.hpa.org.uk/…C/1194947366192.

Pizzo G, Guiglia R, Lo Russo L, Campisi G. Dentistry and internal medicine: From the focal infection theory to the periodontal medicine concept. Eur. J. Intern. Med. 2010 Dec; 21(6): 496-502.

Porter R. The greatest benefit to mankind: A medical history of humanity. 1st ed. New York: WW Norton; 1997

Rabinowitz P, Conti L. One health and emerging infectious diseases: Clinical perspectives. Curr. Top. Microbiol. Immunol. 2012 Set 11;

Raoult D, Drancourt,M. Paleomicrobiology: Past human infections. 1st ed. Berlin: Springer; 2008.

Rechel B, Suhrcke M, Tsolova S, Suk JE, Desai M, McKee M, et al. Economic crisis and communicable disease control in Europe: A scoping study among national experts. Health Policy 2011; 103: 168-75.

Remoli AL, Marsilim G, Battistini A, Sgarbanti M. The development of immune-modulating compounds to disrupt HIV latency. Cytokine Growth Factor Rev. 2012 Aug-Oct; 23(4-5): 159-72.

Russell SJ, Peng KW, Bell JC. Ocolytic virotherapy. Nat. Biotechnol. 2012 Jul 10;30(7): 658-70.

Saade F, Petrovsky N. Technologies for enhanced efficacy of DNA vaccines. Expert Ver. Vaccines 2012 Feb; 11(2): 189-209.

Saunders NA. Application of nanomaterials to arrays for infectious disease diagnosis. Nanomedicine 2011 Feb; 6(2):271-80.

Schreibert W, Mathys FK. Infectio: Doenças infecciosas na história da medicina. 1st ed. Basileia: Edições Roche; 1991.

Semenza JC, Tsolova S, Lim TA. Economic crisis and infectious diseases control: A public health predicament. Eur. J. Pub. Health 2013 Jan 19; 22(1): 5-6

Sherman IW. The power of plagues. 1st ed. Washington: ASM Press; 2006.

Sherman IW. Twelve diseases that changed our world. 1st ed. Washington: ASM Press; 2007.

Silverman RH. The human retrovirus XMRV in the prostate cancer and chronic fatigue syndrome. Nature Reviews Urology 2010 Jul; 7: 392-402.

Sloan CE, Champenois K, Choisy P, Losina E, Walensky RP, Schackman BR, et al. AIDS Jan 2; 26(1): 45-56.

Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, et al. Recommendations for the identification of chronic hepatis C virus infection among persons born during 1945-1965. MMWR 2012 Aug 17; 61(4): 1 – 31.

mith MK, Powers KA, Muessig KE, Miller WC, Cohen MS. HIV treatment as prevention: The utility and limitations of ecological observations. PLos Med Jul; 9(7): e1001260.

Sorrell EM, Schrauwen EJ, Linster M, De Graaf M, Herst S, Fouchier RA. Predicting airborne influenza virus transmission: Mission impossible? Curr. Opin. Virol. 2011 Dec; 1(6): 635-42

Sournia J-C, Ruffie J, As epidemias na história do homem, 1º ed. Lisboa: Edições 70; 1984.

Sournia S. Les épidemies dans l´histoire de l´homme: De la peste au Sida. 1st ed. Paris: Champs Flamarion; 1984

Spagnolo P, Richeldi L, du Bois RM. Environmental triggers and susceptibility factors in idiopathic granulomatous diseases. Semin. Respir. Crit. Care Med. 2008 Dec; 29(6): 610-9.

Stamm LV, Mudrak B. Old foes, New challenges. Fut Microb 2013; 8(2): 177-89.

Stuckler D, Basu S. The international monetary fund´s effects on global heath: Before and after the 2008 financial crisis. Int. J. of Health Serv. 2009; 39(4): 771-781.

Suhrcke M, Stuckler D, Suk JE, Desai M, Senek M, McKee M, et al. The impacto f economic crisis on communicable disease transmission and control: A systematic review of evidence. PLos One 2011 Jun; 6(6): e20724.

Suhrcke M. The economic crisis and infectious disease control. Eurossurveillance 2009 Nov 12; 14(45): pff 19401.

Tabachnick WJ. Challenges in predicting climate and environmental effects on vector-borne disease episystems in a changing world. J. Exp. Biol. 2010 Mar 15; 213(6): 946-54.

Thompson AL. Developmental origins of obesity: Early feeding environments, infant growth, and the intestinal microbiome. Am. J. Hum. Biol. 2012 May-Jun 24; 24(3): 350-60.

Tlaskalova-Hogenova H, Stepancova R, Kozakova H, Hudcovic T, Vannucci T, Tuckova L, et al. The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflamatory and autoimmune diseases and cancer: Contribution of germ-free gnotobiotic animal models of human diseases. Cell Mol. Immunol. 2011 Mar; 8(2): 110-20.

Ujvari SC. A história e as suas epidemias: A convivência do homem com os microorganismos. 1ª ed. Rio de Janeiro: Senac Rio; 2003.
van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoelendat EG, de Vos WM, et al. Duodenal infusion of donnor feces for recurrent clostridium difficile. NEJM 2013 Jan 31; 368(5): 407-15

Vittecoq M, Thomas F, Jourdain E, Moutou, F, Renaud F, Gauthier-Clerc M. Risk of emerging infectious diseases: Evolving threats ina changing área, the mediterranean basin. Transb. and Emerg. Dis. 2012 Set 24 doi: 10111/ bed. 12012.

Walensky P. Cost-effectiviness of HV interventions: From cohort studies and clinical trials to policy. Topics in HIV Med. 2009 Sep/Oct, 17(4): 130 – 134.

Weaver SC, Reisen WK. Present and Future arboviral threats. Antiviral Res. 2010 Feb; 85(2): 328-45.

Woodrow KA, Bennett KM, Lo DD. Mucosal vaccine design and delivary. Annu. Ver. Biomed. Eng. 2012; 14: 17-46.

Woolhouse M. How to make predictions about future infectious diseases risks. Phil. Trans. R. Soc. B. 2011; 366: 2045-54.

Zeller SJ, Kumar P. RNA-based gene therapy for treatment and prevation of HIV: From bench to bedside. Yale J. Biol. Med. 2011 Sep; 84(3): 301-9.